HEALIOS K.K.
4593 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 千代田区有楽町一丁目７番１号
- Website:
- https://www.healios.co.jp/en/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
HEALIOS K.K. is a pioneering Japanese biotechnology company focused on the research and development of innovative cell therapies and regenerative medicine. With a commitment to addressing serious and life-threatening diseases, HEALIOS leverages advanced technologies to create effective treatments for conditions with limited or no existing therapies. The company has received Fast Track and RMAT designations, expediting the approval process for its groundbreaking cellular products. HEALIOS is dedicated to advancing solutions for critical health challenges, including cancers such as mesothelioma, lung cancer, hepatocellular carcinoma, as well as retinal pigment epithelium disorders, thereby contributing to the future of healthcare.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-13 08:33 |
Inside Information Statement
臨時報告書
|
Japanese | 19.7 KB | |
| 2025-03-27 07:22 |
Inside Information Statement
臨時報告書
|
Japanese | 25.4 KB | |
| 2025-03-27 07:21 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2025-03-27 07:20 |
Internal Control over Financial Reporting
内部統制報告書－第14期(2024/01/01－2024/12/31)
|
Japanese | 21.7 KB | |
| 2025-03-27 07:19 |
Annual Report
有価証券報告書－第14期(2024/01/01－2024/12/31)
|
Japanese | 2.0 MB | |
| 2025-02-14 05:13 |
Regulatory News Service
訂正臨時報告書
|
Japanese | 37.5 KB | |
| 2025-02-14 04:07 |
Inside Information Statement
臨時報告書
|
Japanese | 21.3 KB | |
| 2025-01-27 07:31 |
Prospectus
有価証券届出書（参照方式）
|
Japanese | 224.3 KB | |
| 2025-01-22 07:33 |
Inside Information Statement
臨時報告書
|
Japanese | 53.3 KB | |
| 2024-11-13 07:34 |
Inside Information Statement
臨時報告書
|
Japanese | 20.0 KB | |
| 2024-08-13 08:04 |
Inside Information Statement
臨時報告書
|
Japanese | 19.9 KB | |
| 2024-08-13 08:04 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2024-08-13 08:03 |
Interim Report
半期報告書－第14期(2024/01/01－2024/12/31)
|
Japanese | 402.0 KB | |
| 2024-05-13 09:22 |
Inside Information Statement
臨時報告書
|
Japanese | 19.9 KB | |
| 2024-05-13 09:21 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nippon Shinyaku Co.,Ltd. | Japan | 4516 | |
|
Noile-Immune Biotech Inc. | Japan | 4893 | |
|
Novartis AG | Switzerland | NOVN | |
|
Nur Ink Innovations Ltd. | Israel | NURI | |
|
Nxera Pharma Co., Ltd. | Japan | 4565 | |
|
ObsEva SA | Switzerland | OBSN | |
|
ODI Pharma AB | Sweden | ODI | |
|
Oncolys BioPharma Inc. | Japan | 4588 | |
|
OncoTherapy Science, Inc. | Japan | 4564 | |
|
OncoZenge AB | Sweden | ONCOZ |